Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATEMD: Triamcinolone and Bevacizumab for Diabetic Macular Edema
NCT00737971Phase 4Completed
- Start
- Aug 2008
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bevacizumab and triamcinolone in diabetic macular edema (DME). Primary endpoint: Visual Acuity (E Snellen). Started Aug 2008; status: completed.
02
Drugs
bevacizumabtriamcinolone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00737971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00737971.